GJGuillermo Juárez-Vega

Guillermo Juárez-Vega

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guillermo Juárez-Vega has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Disrupted Neutrophil and Myeloid Cell Homeostasis and Effector Dysfunction Drive Vasculopathy in Idiopathic Inflammatory Myopathies

    by Daniel Alberto Carrillo-Vázquez, Beatriz Alcalá-Carmona, Jennifer Tiaré Balderas Miranda, Yatzil Reyna-Juárez, María José Ostos-Prado, Fabiola Cassiano-Quezada, Samuel Govea-Peláez, Nancy R. Mejía-Domínguez, Guillermo Juárez-Vega, Karina Santana-De Anda, et al.

    Background: Neutrophils play a role in idiopathic inflammatory myopathies (IIMs), especially in vasculopathic manifestations. While neutrophil extracellular traps (NETs) and low-density granulocytes (LDGs) have been described, the functional relevance of other subsets—such as naïve neutrophils, reverse transendothelial migration neutrophils (rTEM), myeloid-derived suppressor cells (MDSCs), and regulatory neutrophils—and their association with vasculopathy remains unknown. Objective: We aimed to characterize the phenotypic and functional profile of neutrophil subsets and their association with vasculopathic manifestations in IIM, adjusting for disease activity. Methods: We conducted a cross-sectional, single-center study including 59 IIM patients diagnosed by muscle biopsy and fulfilling 2017 ACR/EULAR criteria. Flow cytometry was used to immunophenotype myeloid subsets, and functional assays assessed phagocytosis and respiratory burst. Patients were stratified by clinical activity and presence of vasculopathy. Results: Vasculopathic patients showed expansion of LDGs (p = 0.0092), granulocytic and monocytic MDSCs expressing Arginase-1 (p = 0.0078, p = 0.0003) and PD-L1 (p = 0.0258, p = 0.0087), and rTEM neutrophils (p = 0.0775). In contrast, they exhibited a reduction in naïve neutrophils (p = 0.0004), phagocytosis (p < 0.0001) and respiratory burst (p = 0.0006). Multivariate analysis identified naïve neutrophils and activated CD177+ neutrophils as independent predictors of vasculopathy. A positive correlation between activated and naïve neutrophils were observed in patients with vasculopathic features (r = 0.43; p < 0.05). Conclusions: IIM patients with vasculopathic features display a distinct immune profile characterized by an imbalance between proinflammatory and regulatory neutrophil subsets, alongside persistent functional impairment.

  • Disease activity and immune disbalance are key drivers of infections in patients with idiopathic inflammatory myopathies: results from the MYOTReCSZ cohort

    by Karina Santana-De-Anda, Jiram Torres-Ruiz, Nancy R Mejía-Domínguez, Fernando Cornejo-Sarmiento, Victor Tovar-Méndez, Beatriz Alcalá-Carmona, Yatzil Reyna-Juárez, María José Ostos-Prado, Guillermo Juárez-Vega, Diana Gómez-Martín

    Patients with idiopathic inflammatory myopathies (IIM) are at increased risk for infections. Identifying clinical and immunological biomarkers predictive of infection is essential. We included 169 patients from the MYOTReCSZ cohort, all with ≥ 6 months of follow-up. Clinical data and laboratory parameters were collected, including: (1) low-density granulocytes and monocyte subsets, (2) serum cytokines, and (3) neutrophil extracellular trap (NET) quantification. The primary outcome was infection development. Most patients were female (72.78%), with a median age of 42. At least one infection occurred in 46.7% of patients; 55.6% were severe and 32.9% had recurrent infections. Independent predictors of infection included number of immunosuppressants (OR 1.7, P = 0.023), gastrointestinal activity score, cardiovascular damage-VAS, anti-Jo1 positivity (OR 10.0, P = 0.05), heliotrope rash, alopecia, and mycophenolate mofetil use (OR 11.9, P = 0.026). Severe infections were associated with number of immunosuppressants, low albumin, constitutional activity score, gastrointestinal damage-VAS, and TLR4⁺ intermediate monocytes (OR 1.0, P = 0.038). Recurrent infections correlated with lower TLR2⁺ classical monocytes (OR 0.4, P = 0.045), cumulative prednisone dose, global damage-VAS (OR 2.0, P = 0.0004), and anti-PM/Scl75 positivity (OR 3.8, P = 0.006). In conclusion, IIM patients with higher baseline activity and damage scores, specific autoantibodies, and altered innate immune cell phenotypes are more likely to develop infections. These parameters may serve as early biomarkers to stratify infection risk in clinical practice.

  • Open Access

    Dermatomyositis-Related Encephalopathy: Clinical, Neuroimaging and Immunological Characterization

    by Daniel Alberto Carrillo-Vázquez, Carlos Antonio Davizon-López, Alejandro Gutiérrez-Castillo, Jiram Torres-Ruiz, Alfredo Pérez-Fragoso, Beatriz Alcalá-Carmona, Alejandro Barrera-Godínez, Guillermo Juárez-Vega, Lidia Antonia Gutiérrez-Gutiérrez, Rodrigo Hernández-Ramírez, et al.

    Background/Objectives: Dermatomyositis (DM) is an autoimmune disease with rarely reported central nervous system involvement, such as encephalopathy. However, no objective characterization of dermatomyositis patients with neurocognitive decline has been previously addressed. Methods: Herein, we describe the immunophenotype, clinical, and neuroimaging features of three DM patients with encephalopathy. Results: The neurocognitive profile of the three patients was characterized by abnormalities in attention, working memory, and language. PET/CT demonstrated temporal and occipital cortical hypometabolism with hypermetabolism in the mesial temporal region, cerebellar, and basal nuclei. The peripheral immunophenotype of DM patients with encephalopathy demonstrated enhanced expression of PD-1+ in CD4+ and CD8+ T cells in comparison with DM patients without encephalopathy. In comparison to healthy controls, DM patients with encephalopathy had increased naïve CD4+, CD57+, and CD4+ T cells, effector memory (TEM), and CD73+ and CD8+ T cells. Additionally, the normalization of cerebral metabolism and clinical behavior after immunosuppressive treatment was evidenced. Conclusions: The PET/CT profile and peripheral immunophenotype (PD-1+, TEM, CD57+, and CD73+) could help to recognize DM patients who are prone to developing encephalopathy symptoms in order to avoid sequelae.

  • Open Access

    Estandarización de zimosán opsonizado como estímulo en la técnica de la 1,2,3-dihidrorrodamina para evaluar el estallido respiratorio del neutrófilo

    by Uriel Pérez-Blanco, Jenniffer Yissel Girón, Guillermo Juárez -Vega, María Jiménez, Carlos Sánchez, Ricardo Rioja, Sara Espinosa-Padilla, Lizbeth Blancas-Galicia

    Introducción. La enfermedad granulomatosa crónica es un defecto de la fagocitosis por deficiencia de gp91phox, p22phox, p47phox, p40phox y p67phox (forma clásica). Recientemente, se describió la deficiencia de EROS y p40phox como responsables de la forma no clásica. La técnica de oxidación de la 1,2,3-dihidrorrodamina –usando como estímulo el forbol-12-miristato-13-acetato– se utiliza para el diagnóstico de la enfermedad granulomatosa crónica clásica. Sin embargo, para la detección de la oxidación mediada por EROS y p40phox, se requiere de otros estímulos como zimosán, Escherichia coli o Staphylococcus aureus.Objetivo. Estandarizar el estímulo con zimosán en la técnica de la 1,2,3-dihidrorrodamina para evaluar el estallido respiratorio del neutrófilo.Materiales y métodos. Se obtuvo sangre de cinco sujetos sanos previo consentimiento informado. Se utilizó la técnica de 1,2,3-dihidrorrodamina usando el forbol-12-miristato-13-acetato como control y diferentes cantidades de zimosán opsonizado (150, 100, 50, 20 y 10 μg). Por citometría de flujo, se obtuvo la intensidad de fluorescencia media de la rodamina 1,2,3 en las poblaciones de neutrófilos y se calculó el índice de oxidación. Se utilizaron las pruebas de Kolmogorov-Smirnov, ANOVA y el análisis post-hoc de Tukey. Se consideró un valor de p ≤ 0,05 como estadísticamente significativo.Resultados. El forbol-12-miristato-13-acetato incrementó la intensidad de la fluorescencia media de la rodamina 1,2,3 en los sujetos sanos. Entre las diferentes condiciones de zimosán probadas, la de 50 μg fue la cantidad óptima y reproducible en todos los controles por el análisis estadístico y los hallazgos citométricos.Conclusiones. Se presenta la optimización de la técnica 1,2,3-dihidrorrodamina empleando el zimosán como estímulo.


  • Open Access

    Urine Extracellular Vesicles Size Subsets as Lupus Nephritis Biomarkers

    by Itze C. Navarro-Hernandez, Raúl F. Reyes-Huerta, Mariana Cañez-Hernández, Jiram Torres-Ruiz, Daniel A. Carrillo-Vázquez, Laura P. Whittall-García, David E. Meza-Sánchez, Guillermo Juárez-Vega, Diana Gómez-Martin, José M. Hernández-Hernández, et al.

    Systemic lupus erythematosus (SLE) is an autoimmune disorder that often leads to kidney injury, known as lupus nephritis (LN). Although renal biopsy is the primary way to diagnose LN, it is invasive and not practical for regular monitoring. As an alternative, several groups have proposed urinary extracellular vesicles (uEVs) as potential biomarkers for LN, as recent studies have shown their significance in reflecting kidney-related diseases. As a result, we developed a flow cytometry approach that allowed us to determine that LN patients exhibited a significantly higher total uEV concentration compared to SLE patients without kidney involvement. Additionally, an analysis of different-sized uEV subsets revealed that microvesicles ranging from 0.3 to 0.5 μm showed the most promise for distinguishing LN. These findings indicate that evaluating uEV concentration and size distribution could be a valuable diagnostic and monitoring tool for LN, pending further validation in more comprehensive studies.


  • Open Access

    Blockade of the CCR3 receptor reduces neutrophil recruitment to the lung during acute inflammation

    by Fatima Lopez-Leal, Tecilli Cabellos-Avelar, Diego A Correa-Becerril, Brenda Juarez-Macias, Rodrigo Cervantes-Diaz, Raul F Reyes-Huerta, Guillermo Juarez-Vega, Daniel Gutierrez-Castaneda, Tannya Karen Castro-Jimenez, Jose Bustos-Arriaga, et al.

    Neutrophils represent one of the host's first lines of defense against invading pathogens. However, an aberrant activation can cause damage to the host. In the case of respiratory infections with viral or bacterial pathogens, one of the most common complications is the development of acute respiratory distress syndrome (ARDS), in which neutrophil infiltration into the lung is a hallmark. Neutrophils gain expression of chemokine receptors under inflammatory conditions, and their activation can amplify the neutrophil responses. Earlier studies showed that neutrophils recruited to the lung mucosa during bacterial infection upregulate expression of CCR3 and ex vivo stimulation of CCR3 results in an increased neutrophil activation. Therefore, the modulation of effector functions or migration of neutrophils to target sites through chemokine receptors constitutes an opportunity for pharmacological intervention. We aimed to determine whether the blockade of the CCR3 using the specific antagonist SB-328437 reduces neutrophil recruitment and inflammation in the lung in the LPS-induced lung injury model and influenza infection in mice. We found that neutrophils acquire CCR3 expression in the lung alveolar space. The intraperitoneal administration of SB-328437 reduced neutrophil recruitment to the lung alveolar space and reduced tissue damage in both the LPS-induced lung injury model and influenza infection. Moreover, treatment with SB-328437 reduced the percentage of neutrophils producing TNFα and neutrophil activation in the alveolar space. Together, these data suggest that CCR3 blockade might be a pharmacological strategy to prevent the aberrant neutrophil activation that results detrimental for the host but preserves sufficient effector response to control the pathogen.


  • Open Access

    Novel Clinical, Immunological, and Metabolic Features Associated with Persistent Post-Acute COVID-19 Syndrome

    by Karina Santana-De Anda, Jiram Torres-Ruiz, Nancy R. Mejía-Domínguez, Beatriz Alcalá-Carmona, José L. Maravillas-Montero, José Carlos Páez-Franco, Ana Sofía Vargas-Castro, Jaquelin Lira-Luna, Emmanuel A. Camacho-Morán, Guillermo Juarez-Vega, et al.

    The coronavirus disease 2019 (COVID-19) survivors are frequently observed to present persistent symptoms constituting what has been called “post-acute COVID-19 syndrome” (PACS) or “long COVID-19”. Some clinical risk factors have been identified to be associated with PACS development; however, specific mechanisms responsible for PACS pathology remain unknown. This study investigates clinical, immunological, and metabolomic risk factors associated with post-acute COVID-19 syndrome (PACS) in 51 patients, assessed 7–19 months after acute infection. Among the participants, 62.7% were male and 37.2% were female, with an average age of 47.8 years. At the follow-up, 37.2% met the criteria for PACS, revealing significant differences in immunological and metabolomic profiles at the time of acute infection. Patients with PACS were characterized by elevated levels of mature low-density granulocytes (LDGs), interleukin-8 (IL-8), pyruvate, pseudouridine, and cystine. Baseline multivariate analysis showed increased pyruvate and decreased alpha tocopherol levels. At follow-up, there was a decrease in absolute B lymphocytes and an increase in non-classical monocytes and 3-hydroxyisovaleric acid levels. These findings suggest that specific immunological and metabolomic markers during acute infection can help identify patients at higher risk of developing persistent PACS.


  • Open Access

    FANSY POSTCOV: A composite clinical immunological predictive index for post‐COVID‐19 syndrome unveils distinctive features in a cohort study of mild to critical patients

    by Jiram Torres‐Ruiz, Julieta Lomelín‐Gascón, Jaquelin Lira‐Luna, Alfredo Pérez‐Fragoso, Roberto Tapia‐Conyer, Miroslava Nuñez‐Aguirre, Beatriz Alcalá‐Carmona, Abdiel Absalón‐Aguilar, José Luis Maravillas‐Montero, Nancy Raquel Mejía‐Domínguez, et al.